AR115991A1 - EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN - Google Patents

EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN

Info

Publication number
AR115991A1
AR115991A1 ARP190102374A ARP190102374A AR115991A1 AR 115991 A1 AR115991 A1 AR 115991A1 AR P190102374 A ARP190102374 A AR P190102374A AR P190102374 A ARP190102374 A AR P190102374A AR 115991 A1 AR115991 A1 AR 115991A1
Authority
AR
Argentina
Prior art keywords
visual
individual
compound
formula
pharmaceutically acceptable
Prior art date
Application number
ARP190102374A
Other languages
English (en)
Spanish (es)
Inventor
Miguel Alcantara
Wayne Chen
Daniel W Gil
Mohammed Dibas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR115991A1 publication Critical patent/AR115991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP190102374A 2018-08-21 2019-08-21 EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN AR115991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21

Publications (1)

Publication Number Publication Date
AR115991A1 true AR115991A1 (es) 2021-03-17

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102374A AR115991A1 (es) 2018-08-21 2019-08-21 EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN

Country Status (17)

Country Link
US (4) US20210205273A1 (enExample)
EP (1) EP3840750A1 (enExample)
JP (1) JP2021534217A (enExample)
KR (1) KR20210047323A (enExample)
CN (1) CN112823003A (enExample)
AR (1) AR115991A1 (enExample)
AU (1) AU2019325486A1 (enExample)
BR (1) BR112021003295A2 (enExample)
CA (1) CA3110318A1 (enExample)
CL (1) CL2021000440A1 (enExample)
CO (1) CO2021003460A2 (enExample)
IL (1) IL280990A (enExample)
MX (1) MX2021002112A (enExample)
PH (1) PH12021550372A1 (enExample)
SG (1) SG11202101730SA (enExample)
TW (1) TW202021584A (enExample)
WO (1) WO2020041340A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514732A (ja) * 2020-02-20 2023-04-07 アラーガン、インコーポレイテッド アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用
WO2022182740A1 (en) 2021-02-24 2022-09-01 Ocular Therapeutix, Inc. Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
WO2012149381A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
ES2751681T3 (es) 2013-03-15 2020-04-01 Allergan Inc Implante intraocular que contiene prostamida
EP2978406A1 (en) 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
WO2014165308A2 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Also Published As

Publication number Publication date
IL280990A (en) 2021-04-29
CA3110318A1 (en) 2020-02-27
WO2020041340A1 (en) 2020-02-27
CL2021000440A1 (es) 2021-09-20
EP3840750A1 (en) 2021-06-30
KR20210047323A (ko) 2021-04-29
BR112021003295A2 (pt) 2021-05-18
US20220288031A1 (en) 2022-09-15
SG11202101730SA (en) 2021-03-30
US20240358682A1 (en) 2024-10-31
AU2019325486A1 (en) 2021-03-25
US20210205273A1 (en) 2021-07-08
JP2021534217A (ja) 2021-12-09
PH12021550372A1 (en) 2021-11-29
TW202021584A (zh) 2020-06-16
CO2021003460A2 (es) 2021-04-08
MX2021002112A (es) 2021-07-16
CN112823003A (zh) 2021-05-18
US20220160623A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CO2020014563A2 (es) Uso de clorhidrato de pilocarpina para el tratamiento de condiciones oculares
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
MX2025015186A (es) Inhibidores de pi3k y uso de estos
CL2017002526A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015)
PE20212077A1 (es) Nuevos compuestos sulfonamida de carboxamida
RU2017115563A (ru) Композиции и способы лечения дисфункции мейбомиевых желез
WO2016172712A3 (en) Ophthalmic composition
MX2019001877A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
RU2013142602A (ru) Композиции и способы для нехирургического лечения птоза
EP4324454A3 (en) Cross-linking agents and associated methods
MY204185A (en) Composition and methods for the treatment of myopia
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
AR119122A2 (es) Soluciones intracamerales antiinflamatorias y midriáticas para la inhibición de las afecciones inflamatorias oculares postoperatorias
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
PH12021550372A1 (en) The use of alpha-2-adrenergic receptor agonists for improving vision
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
ES2421405T3 (es) Composiciones que comprenden un agonista del receptor de glucocorticoides disociado para tratar o controlar una inflamación del segmento anterior
EA202193211A1 (ru) Лечение синуклеопатий
EA202190034A1 (ru) Вещества, ингибирующие ask1
RU2016124102A (ru) Способ лечения офтальмологических расстройств с помощью соединений, обнаруженных в секретах железы мигательной перепонки

Legal Events

Date Code Title Description
FA Abandonment or withdrawal